Teligent Announces FDA Approval of Fluocinonide Cream USP, 0.05%

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Fluocinonide Cream USP, 0.05%.

As quoted in the press release:

This is Teligent’s eleventh approval for 2018, and its thirtieth approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

Based on recent IQVIA data from August 2018, the total addressable market for this product is approximately $33.1 million.

“I am excited about our most recent approval,’’ commented Jason Grenfell-Gardner, President and CEO of the Company. “Teligent is committed to providing patients and physicians with pharmaceutical products of uncompromising quality and value.”

Mr. Grenfell-Gardner continued, “We now have thirty-five topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

Click here to read the full press release.